PMC:7200337 / 75278-76148 JSONTXT

{"project":"2_test","denotations":[{"id":"32505227-30724789-46575388","span":{"begin":420,"end":424},"obj":"30724789"},{"id":"T127","span":{"begin":420,"end":424},"obj":"30724789"}],"text":"A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T671","span":{"begin":302,"end":305},"obj":"Body_part"}],"attributes":[{"id":"A671","pred":"fma_id","subj":"T671","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T450","span":{"begin":379,"end":388},"obj":"Disease"},{"id":"T451","span":{"begin":389,"end":399},"obj":"Disease"},{"id":"T452","span":{"begin":549,"end":557},"obj":"Disease"},{"id":"T453","span":{"begin":558,"end":567},"obj":"Disease"},{"id":"T454","span":{"begin":828,"end":836},"obj":"Disease"}],"attributes":[{"id":"A450","pred":"mondo_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A451","pred":"mondo_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A452","pred":"mondo_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A453","pred":"mondo_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A454","pred":"mondo_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T852","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T853","span":{"begin":93,"end":94},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T854","span":{"begin":198,"end":199},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T855","span":{"begin":280,"end":281},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T856","span":{"begin":477,"end":478},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T857","span":{"begin":571,"end":575},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T858","span":{"begin":744,"end":745},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T859","span":{"begin":854,"end":855},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3679","span":{"begin":53,"end":68},"obj":"Chemical"},{"id":"T188","span":{"begin":53,"end":62},"obj":"Chemical"},{"id":"T55339","span":{"begin":63,"end":68},"obj":"Chemical"},{"id":"T77180","span":{"begin":154,"end":164},"obj":"Chemical"},{"id":"T87089","span":{"begin":176,"end":183},"obj":"Chemical"},{"id":"T80088","span":{"begin":185,"end":195},"obj":"Chemical"},{"id":"T34736","span":{"begin":215,"end":224},"obj":"Chemical"},{"id":"T12481","span":{"begin":251,"end":270},"obj":"Chemical"},{"id":"T23126","span":{"begin":251,"end":260},"obj":"Chemical"},{"id":"T70643","span":{"begin":261,"end":270},"obj":"Chemical"},{"id":"T26566","span":{"begin":302,"end":325},"obj":"Chemical"},{"id":"T198","span":{"begin":306,"end":325},"obj":"Chemical"},{"id":"T12781","span":{"begin":315,"end":325},"obj":"Chemical"},{"id":"T43786","span":{"begin":327,"end":338},"obj":"Chemical"},{"id":"T54451","span":{"begin":348,"end":357},"obj":"Chemical"},{"id":"T98765","span":{"begin":431,"end":441},"obj":"Chemical"},{"id":"T54422","span":{"begin":576,"end":587},"obj":"Chemical"},{"id":"T450","span":{"begin":591,"end":598},"obj":"Chemical"},{"id":"T360","span":{"begin":864,"end":869},"obj":"Chemical"}],"attributes":[{"id":"A24549","pred":"chebi_id","subj":"T3679","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A7218","pred":"chebi_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A32212","pred":"chebi_id","subj":"T55339","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A55887","pred":"chebi_id","subj":"T77180","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A42365","pred":"chebi_id","subj":"T87089","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A96945","pred":"chebi_id","subj":"T80088","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A56943","pred":"chebi_id","subj":"T34736","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A81124","pred":"chebi_id","subj":"T12481","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A39131","pred":"chebi_id","subj":"T23126","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A62159","pred":"chebi_id","subj":"T70643","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A39211","pred":"chebi_id","subj":"T26566","obj":"http://purl.obolibrary.org/obo/CHEBI_35660"},{"id":"A85115","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A57400","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A60634","pred":"chebi_id","subj":"T12781","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A43154","pred":"chebi_id","subj":"T43786","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A20735","pred":"chebi_id","subj":"T54451","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A13887","pred":"chebi_id","subj":"T98765","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A47043","pred":"chebi_id","subj":"T54422","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A57497","pred":"chebi_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A31951","pred":"chebi_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2440","span":{"begin":343,"end":347},"obj":"Gene"},{"id":"2441","span":{"begin":647,"end":649},"obj":"Gene"},{"id":"2442","span":{"begin":568,"end":570},"obj":"Gene"},{"id":"2443","span":{"begin":363,"end":365},"obj":"Gene"},{"id":"2444","span":{"begin":525,"end":533},"obj":"Species"},{"id":"2445","span":{"begin":804,"end":812},"obj":"Species"},{"id":"2446","span":{"begin":379,"end":388},"obj":"Species"},{"id":"2447","span":{"begin":176,"end":183},"obj":"Chemical"},{"id":"2448","span":{"begin":185,"end":195},"obj":"Chemical"},{"id":"2449","span":{"begin":251,"end":270},"obj":"Chemical"},{"id":"2450","span":{"begin":272,"end":277},"obj":"Chemical"},{"id":"2451","span":{"begin":327,"end":338},"obj":"Chemical"},{"id":"2452","span":{"begin":431,"end":441},"obj":"Chemical"},{"id":"2453","span":{"begin":576,"end":587},"obj":"Chemical"},{"id":"2454","span":{"begin":591,"end":598},"obj":"Chemical"},{"id":"2455","span":{"begin":621,"end":632},"obj":"Chemical"},{"id":"2456","span":{"begin":389,"end":399},"obj":"Disease"},{"id":"2457","span":{"begin":549,"end":557},"obj":"Disease"},{"id":"2458","span":{"begin":558,"end":567},"obj":"Disease"},{"id":"2459","span":{"begin":828,"end":836},"obj":"Disease"}],"attributes":[{"id":"A2440","pred":"tao:has_database_id","subj":"2440","obj":"Gene:43740578"},{"id":"A2441","pred":"tao:has_database_id","subj":"2441","obj":"Gene:6999"},{"id":"A2442","pred":"tao:has_database_id","subj":"2442","obj":"Gene:6999"},{"id":"A2443","pred":"tao:has_database_id","subj":"2443","obj":"Gene:6999"},{"id":"A2444","pred":"tao:has_database_id","subj":"2444","obj":"Tax:9606"},{"id":"A2445","pred":"tao:has_database_id","subj":"2445","obj":"Tax:9606"},{"id":"A2446","pred":"tao:has_database_id","subj":"2446","obj":"Tax:11520"},{"id":"A2447","pred":"tao:has_database_id","subj":"2447","obj":"MESH:C086979"},{"id":"A2448","pred":"tao:has_database_id","subj":"2448","obj":"MESH:C086979"},{"id":"A2449","pred":"tao:has_database_id","subj":"2449","obj":"MESH:C558899"},{"id":"A2450","pred":"tao:has_database_id","subj":"2450","obj":"MESH:C558899"},{"id":"A2451","pred":"tao:has_database_id","subj":"2451","obj":"MESH:C462182"},{"id":"A2452","pred":"tao:has_database_id","subj":"2452","obj":"MESH:C000606551"},{"id":"A2453","pred":"tao:has_database_id","subj":"2453","obj":"MESH:C462182"},{"id":"A2454","pred":"tao:has_database_id","subj":"2454","obj":"MESH:C086979"},{"id":"A2455","pred":"tao:has_database_id","subj":"2455","obj":"MESH:C462182"},{"id":"A2456","pred":"tao:has_database_id","subj":"2456","obj":"MESH:D007239"},{"id":"A2457","pred":"tao:has_database_id","subj":"2457","obj":"MESH:C000657245"},{"id":"A2458","pred":"tao:has_database_id","subj":"2458","obj":"MESH:D007239"},{"id":"A2459","pred":"tao:has_database_id","subj":"2459","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group."}

{"project":"LitCovid-sentences","denotations":[{"id":"T425","span":{"begin":0,"end":92},"obj":"Sentence"},{"id":"T426","span":{"begin":93,"end":454},"obj":"Sentence"},{"id":"T427","span":{"begin":455,"end":620},"obj":"Sentence"},{"id":"T428","span":{"begin":621,"end":687},"obj":"Sentence"},{"id":"T429","span":{"begin":688,"end":870},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A large number of clinical trials using experimental antiviral drugs are currently underway. A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A). Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b). Favipiravir was suggested to significantly improve symptom relief. However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group."}